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Abstract: Malignant aerodigestive fistula (ADF) is an uncommon condition complicating thoracic
malignancies. It results in increased morbidity and mortality and warrants therapeutic intervention. The
management approach depends on symptoms, configuration, location, and extent of the fistula. This article
will discuss the therapeutic considerations in the management of ADF.
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Introduction
Aerodigestive fistula (ADF) is the formation of an
abnormal tract between the airway and the digestive tract,
most commonly the esophagus. Other terms used in the
literature include broncho-esophageal, tracheo-esophageal
or esophagorespiratory fistula.
ADF occurs in 5–15% of patients with esophageal or lung
cancer, but may occur after trauma, or as a complication of
surgery, stent placement and high endotracheal tube cuff
pressure (1).
When occurring in the setting of malignancy such as
lung or esophageal cancers, it is referred to as malignant
ADF. This leads to significant morbidity and mortality as
these patients die from pneumonia, sepsis and malnutrition
within days to weeks if the fistula is left untreated (2-5).
The diagnosis is usually suspected from the clinical
symptoms and the medical history. Thin section computed
tomography (CT) scan of the chest and a contrast
esophagogram provide additional information on the
location of the fistula. Bronchoscopy and endoscopy are
necessary to confirm the diagnosis as well as to plan a
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therapeutic intervention. Visualization of small fistula
can be improved by the administration of oral methylene
blue prior to the bronchoscopy (6), or by the instillation
of the methylene blue in the esophagus while performing
simultaneous bronchoscopic and endoscopic procedures (7).
Different authors have described the location of the ADF. In
a series of 63 patients, malignant ADF fistula most commonly
occurred in the distal third of the trachea in 35%, the middle
third in 29%, and the left main stem bronchus in 14% of the
patients (8). In another series of 59 patients, malignant ADF
occurred in the trachea in 50%, left main bronchus in 32%, and
right main bronchus in 15% of the patients, while involving
the main carina in 3% of the cases (9). In another series of 25
ADF, fistulas were localized to the proximal esophagus in 48%,
the mid-esophagus in 20% and the distal esophagus in 24%
of patients. In 8% (2/25) multiple fistulas were present (1).
Although, most fistulae develop between the central airways
and esophagus, some fistulae develop between the esophagus
or stomach and the distal bronchi, small airways or lung
parenchyma (2,3,10). In patients with esophageal resection for
esophageal cancer, fistula formation can occur between the
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are distressing to patients and can disturb their quality of
life later in the disease course. As such, palliation of these
symptoms is recommended (14).
Bronchoscopic and endoscopic therapy is currently the
main treatment for malignant ADF. In this review, we aim at
providing an update regarding the latest advances of these
various therapeutic approaches.
Endoscopic treatment
Goals of therapy
Patients with TE fistula typically presents with cough and
dyspnea that is related to aspiration of their saliva and/
or gastric contents. This lead to recurrent pulmonary
infections and malnutrition with an increased mortality
when no therapy is provided. Left untreated, patients with
tracheoesophageal (TE) fistula have a median survival of
few days to weeks (2-5,15).
The goals of treatment of the TE fistula is focused on
palliation of the symptoms including cough, shortness of
breath, dysphagia, decreasing the risk of aspiration as well
as on improving the quality of life and survival (16).

Figure 1 Tracheoesophageal fistula. (A) Esophageal view of a 2-mm
fistula (arrow) with surrounding fibrotic mucosa; (B) endoscopic
clip (arrow) was attempted but was not optimal due to the fibrotic
mucosa; (C) the endoscopic clip was removed and covered metallic
stent was placed to cover the fistula.

stomach that was pulled up into the chest and the airways (11).
The course of thoracic malignant diseases differs
significantly from those of benign fistula, and thus
management of ADF should follow a separate approach that
takes in consideration the patients’ symptoms, quality of life
and the estimated life expectancy.
For patients with acquired ADF of benign etiology,
surgery may provide the best outcome as long as the
patient is a good surgical candidate. This includes ADF
division and primary repair, esophageal resection and
reconstruction, esophageal diversion, suture closure of the
fistula, pedicled tissue flap, segmental tracheal or bronchial
resection (12,13).
The majority of patients with malignant ADF have
either an advanced disease, metastasis or a high Eastern
Cooperative Oncology Group (ECOG) score making them
poor surgical candidates. Furthermore, ADF symptoms
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Esophageal stenting only
Esophageal stenting using a self-expanding metallic stent
(SEMS) has been used since 1980 (7). They are the most
frequently used treatment modality (1). They are divided into
partially covered stents and fully covered stents (Figure 1).
While being equally effective at sealing the ADF, the overall
clinical success rate at preventing aspiration range from
54–74% (1,17,18). Partially covered stents tend to embed
in the esophageal wall making them less prone to migration
but have a higher rate of tumor ingrowth. Fully covered
stents have a higher rate of migration (17).
Stent related adverse events have been reported in
around 30% to 37% of cases (18,19), and can be divided
into early events (3%), such as esophageal perforation
and tracheal compression, and late events (27%) such
as stent migration, stent occlusion by tumor growth,
upper gastrointestinal bleeding and stent induced fistula
formation (18).
The most serious complication that can occur during
esophageal stent placement is tracheal compression with
airway compromise. This can occur immediately after
placement of the esophageal stent or may be a delayed
complication (18).
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Airway stenting
Various types of airway stents have been used for palliation
of the symptoms of ADF. These can be divided by type
into partially or fully covered SEMS, silicone stents, and
dynamic stents, or by shape into straight, L-shaped, I-shaped
(cylindrical), hourglass-shaped or Y stent (Table 1).
There is a paucity of trials evaluating the role of airway
stent alone in the management of ADF (Figures 2,3). In
a retrospective case control study, Chung et al. evaluated
31 patients who received airway SEMS only for ADF
and compared them to 28 patients with similar baseline
demographics who were managed conservatively only (9).
Median survival, 90-day mortality and performance status
were higher in the group that received an airway stent.
Compared to the non-stented group’s median survival of
29 days, the group who received airway stent had a median
survival of 69 days.
In another retrospective study done by Wang et al.,
63 patients with malignant ADF who were deemed to be
non-surgical candidates and who were either unsuitable
for esophageal stent, had an airway stenosis or had
a complication from esophageal stenting, received a
customized metallic airway stent for malignant ADF. A
total of 45 metallic Y stents, ten I-shaped stents and eight
L-shaped stents were placed in the airway. Only 8 of these
patients had additional esophageal stenting. Complete
fistula closure was observed in 71.4% of the patients (45/63).
There was an improvement in mean karnofsky score, and an
overall mean survival of 163 days (8).
Huang et al. reported their outcome for 50 patients with
malignant ADF who were managed with esophageal SEMS
only (21/50), airway SEMS only (13/50) or received double
stenting (16/50) (20). The mean survival was 171 days,
with no significant difference between the three groups.
Complete fistula closure was achieved in 28 of the 50
patients (56%), with recurrent ADF in 66% of the patients.
There was no significant difference between the groups.
In 2010, Herth et al. reported one of the largest
prospective trials, evaluating 112 patients with malignant
ADF (21). Thirty-seven patients (33%) received an
esophageal stent only, 65 patients (58%) received an airway
SEMS only, and ten patients (9%) received double stenting.
The mean survival was significantly longer in the group
receiving an esophageal stent only or double stenting when
compared to the group receiving an airway stent only
(269 days vs. 253 and 219 days respectively). The ADF
primary closure was 100% in all groups, but recurrence
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occurred in 24 patients (21%), and was more common in
the airway stent only group (17 patients in the airway stentonly group compared to 6 in the esophageal SEMS-only
and 1 in the double-stent group).
Double stenting
Double stenting (or parallel stenting) refer to the placement
of an airway as well as an esophageal stent. Multiple
studies have reported placement of an esophageal tube (23)
or SEMS (1,20-22,24). The airway stenting was performed
using SEMS (1,20-22,24), Silicone stent (1,22-24),
or dynamic stent (23). In general, these studies are
retrospective and involve a small number of patients. Few
allow a direct comparison between single and double
stenting (20,23,24).
Freitag et al. (23) published a retrospective study including
30 patients with malignant ADF who received either a
Dynamic airway stent alone (12 patients) or combined airway
and esophageal stenting (18 patients). Patients who received
double stents had a longer survival compared with the airway
stent only (110.2 vs. 23.8 days, P=0.0027). Fifty percent of
the patients who received an airway stent only had persistent
dysphagia, compared to 11% in the double-stenting group.
Despite the limitations of the study, the authors concluded
that double stenting may improve survival and quality of life
compared to airway stenting alone.
More recently, Ke and his colleagues (24) reported their
experience in the management of 62 patients with ADF who
received airway and esophageal stenting.
Complete response was defined as no leakage of contrast
medium after digital radiography and resolution of clinical
symptoms without recurrence for more than two weeks.
Partial response was defined as minor leakage of contrast
medium with improvement of clinical symptoms that was
maintained for more than 2 weeks. Failed treatment was
defined as severe leakage of contrast medium with no
improvement in clinical symptoms. Forty-three patients
received an airway SEMS and 25 of the 43 patients received
additional esophageal SEMS (double stenting). Complete
fistula closure occurred in 65 % (28/43) and partial closure
in 35% (15/43) of the patients. When looking at the double
stenting group only, 96% (24/25) achieved complete fistula
closure. Similarly, they inserted 18 airway Dumont silicon
stents in 18 patients. Ten of these patients received double
stenting. Complete fistula closure was noted in 72% (13/18)
and partial closure in 28% (5/18) of the patients. In the
double stenting group, 100% (10/10) achieved complete
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Table 1 Summary of studies assessing the role of airway stenting in the management of Aero Digestive Fistula (ADF)
Study

Type

Patients

Outcomes

Recurrence

Complications

Chung et al.

Retrospective case

59 patients: 31 with

The group that received an airway

–

No major complications

2012 (9)

control in inoperable

airway SEMS, 28 with

stent showed:

patient with malignant

no SEMS



ADF

were reported

Improved median survival:
69 vs. 29 days (P=0.04);



Improved 90-day mortality:
42% vs. 14% (P=0.02);



Less recurrent pneumonia
(58% vs. 96%);


Wang et al.

Retrospective study

63 patients:

2015 (8)

in inoperable patients



Improved performance status

The whole group mean survival was

–

28 patients with chest

Metallic airway

163 days

pain

with malignant ADF

stent in

with airway stenosis,

Complete fistula closure in

Two patients with stent

55 patients

unsuitability for

45 (71.4%) patients

migration

(10 I- ,8 L-,

esophageal stenting

45 Y-shaped);

Incomplete closure in 18 (28.6%)

Two patients with double

patients

stenting had delayed

or complication from



esophageal stenting

Double stenting in

massive hemoptysis

eight patients

Two patients with airway
restenosis

Huang et al.

Retrospective study

50 patients:

2017 (20)

in esophageal cancer





Mean survival of all groups was

Recurrence 33

Five patients with chest

Esophageal

171 days with no difference between

(66%) after follow-

pain after esophageal

SEMS, 21 (42%);

groups

up of 178 days

stenting

Double stenting,

Primary fistula closure in

Some were treated

One patient with massive

16 (32%);

28/50 patients

with overlapping

hemoptysis after tracheal

Airway SEMS,

stent in the

stenting

13 (26%)

esophagus or the
airway
Successful sealing had better
survival (80 vs. 242 days) P<0.01

Herth et al.

Prospective study

112 patients:

2010 (21)

in patients with



malignant ADF


Mean survival of all groups was

Recurrence in

Seven patients with

236 days

24 patients

transient respiratory

SEMS: 37 (33%);

(17 airway,

failure requiring MV

Double stenting:

1 double and

(<1 day) in the ICU

6 esophageal)

(4 airways, 2 double and

after 6 weeks

1 esophageal stent)

Esophageal

10 (9%);


Airway SEMS:
65 (58%)

Higher mean survival for the
esophageal SEMS (269 days) and

requiring a second
stent placement

No stent migration

double stenting (253 days) compared
to airway SEMS only (219 days)
Improved QoL in the whole group

No late complication

100% primary closure in all groups
Higher survival for ADF involving
the trachea/left main and carina
compared to right mainstem
bronchus
Higher survival for double or
esophageal stent only compared to
airway only

Table 1 (continued)
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Table 1 (continued)
Study

Type

Patients

Outcomes

Recurrence

Complications

Silon et al.

Retrospective study in

25 patients:

2017 (1)

patients with benign



and malignant ADF

Esophageal SEMS: fistula closure

Esophageal

Minor complications in

Esophageal

54% (7/13), average survival

SEMS: repeat

40% (10/25) patients

SEMS, only 13/25

6 months

procedure in 5/13

including: stent migration,

(38%) patients

pain, dysphagia, bleeding,

(52%);



Double stent 6/25

Double stenting: fistula closure 33%

Double stent:

(24%);

(2/6), average survival 3 months

repeat procedure

Y [2] + airway

in 2/6 (33%)

SEMS [4]

patients

reflux, pneumonia, stent
infolding and foreign body
sensation

Proximal ADF location—low success
rate, high recurrence of aspiration,
shortest survival
Włodarczyk

Retrospective

31 patients with double

Total mean survival of 68 days

Recurrent fistula

Fatal bleeding in one

et al. 2016

in patients with

stenting:

(3–169 days)

in 13% (4/31)

patient on day 3 post

(22)

inoperable malignant



patients

operation

ADF

Esophageal
partially covered

Improved Karnofsky score Improved

Seven patients died of

SEMS + Y stent

dyspnea and dysphagia

bleeding in long-term

(25/31);


follow-up

Esophageal

One patient with

partially covered

obliteration of tracheal

SEMS + partially

stent by granulation tissue

covered SEMS

One patient with

(8/31)

esophageal stent
migration

Freitag et al.

Retrospective with

30 patients:

1996 (23)

malignant ADF





Y stent

Airway stent only: mean survival of

Three dislodgements of

Y stent (18/30);

24 days

esophageal tube

Airway dynamic Y

Retrospective with

61 patients:

2015 (24)

malignant ADF





Migration of one dynamic

+ airway dynamic

Ke et al.



–

110 days

stent (12/30)



Double stenting: mean survival of

Esophageal tube

Improved dyspnea and dysphagia in
all groups

Airway SEMS: complete closure,

Airway SEMS:

28/43 (65%); partial closure, 15/43

43 patients;

(34.9%); double stenting: complete

Double stenting in

closure, 24/25 (96%)

25/43;

Airway silicone stent: complete

Airway silicone

closure, 13/18 (72%); partial closure,

stent: 18 patients;

5/18 (28%); double stenting:

Double stenting:

complete closure, 10/10 (100%)

10/18

Metallic stents and silicone stents

–

–

show equivalent clinical effects

ADF, aerodigestive fistula; SEMS, self-expanding metallic stent; QOL, quality of life; MV, mechanical ventilation.

fistula closure. The authors concluded that double stenting
of the trachea and esophagus can achieve the best clinical
benefit, and that metallic stents and silicone stents show
equivalent clinical effects.

© Journal of Thoracic Disease. All rights reserved.

These results contrast with those reported by Huang
et al. (20), who did not find a survival difference between
patients who received single esophageal, single airway stent
or double stenting.
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Figure 2 Bronchoesophageal fistula. (A) Axial chest CT showing the bronchoesophageal fistula (arrow) between the bronchus intermedius
and the gastric pull through (post esophageal resection for esophageal cancer); (B) sagital chest CT showing the fistula (arrow); (C)
bronchoscopic view showing the fistula in the bronchus intermedius (arrow); (D) bronchoscopic view showing the gastric fluid leaking
through the fistula (arrow) of the bronchus intermedius; (E) endoscopic view showing the gastric fistula (arrow); (F) bronchoscopic view
showing a fully covered self-expandable metallic stent deployed in the bronchus intermedius and covering the fistula.

Overlapping stent
Overlapping refers to the insertion of a second stent in the
same lumen (esophageal or airway) in which a previous stent
exists, in order to allow sealing and occlusion of a previously
stented fistula with incomplete closure. The two stents
usually overlap over a small distance (Figure 4). Multiple
studies have described this technique in the management of
recurrent fistulae (20,21).
Approach to initial stent placement: esophageal versus
airway stent
In general, an airway stent should be placed first when
there is a concern for airway compromise, when there is a
contraindication for esophageal stenting such as esophageal
obstruction with inability to pass the wire beyond the

© Journal of Thoracic Disease. All rights reserved.

obstruction, if the ADF is located in the upper third of the
esophagus or if it is technically difficult to place a stent such
in the case of gastro-tracheal fistula (Figure 2). In patients
with sufficient nutrition that is provided via percutaneous
endoscopic gastrostomy, an airway stent only may also be
inserted (23).
If none of the above conditions are met, it appears that
esophageal stent only or double stenting have an advantage
over airway stenting alone. The American College of Chest
Physicians gives a grade 1B recommendation for double
stenting of the esophagus and bronchial tree or the esophagus
alone with SEMS while managing patients with ADF (16).
Technical part
In general, a multidisciplinary approach by the endoscopist
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Figure 3 Bronchoesophageal fistula. (A) Axial chest CT scan showing the bronchoesophageal fistula between esophagus and left main stem
(arrow); (B) barium swallow showing the bronchoesophageal fistula (arrow); (C) bronchoscopic view showing the large fistula of the left
main stem; (D) bronchoscopic view showing a fully covered stent in place covering the left main stem bronchoesophageal fistula.

and the bronchoscopist is recommended to provide the
optimal treatment of the ADF.
An airway evaluation to determine the degree of airway
compromise should be done prior to the insertion of any
esophageal stent. If there is visible airway narrowing, an
airway stent should be placed first. In cases where there is
suspicion of impending airway compromise after esophageal
stent placement, simultaneous dual esophagostomy and
bronchoscopy during which a balloon can be inflated in the
esophagus to a diameter equal to that of the esophageal stent
with direct bronchoscopic evaluation should be done (25).
If significant airway narrowing develops, the airway
should be stented first prior to esophageal stenting (26).
If an airway stent is placed first, it should be followed by
placement of an appropriately sized esophageal stent, since
the outcome of double stenting appears better than single
airway stent. If an esophageal stent is placed first it should

© Journal of Thoracic Disease. All rights reserved.

be followed by an esophagogram in few days to detect
persistent leak. If such a leak is present an airway stent
should be placed (Figure 5).
The optimal stent length should be chosen to cover at
least 2 cm beyond the proximal and distal margin of the
lesion. The stent diameter should be at least 10–20% larger
than the normal internal airway adjacent to the fistula (24).
The choice of the airway stent depends on the location
of the fistula. Sites with close proximity to the carina may
benefit from a customized silicone Y stent or dynamic
airway stent placement, otherwise an appropriately sized
SEMS or a silicone tube stent can be placed.
Metal stents can be placed with flexible bronchoscopy
under direct or indirect visualization, using fluoroscopic
guidance. Metal stent are composed of different metal alloys
that gives them their radial force and metallic memory, which
allows them to self-expend after deployment. They can adapt
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Figure 4 Complicated aerodigestive fistula. (A) Endobronchial view of a malignant aerodigestive fistula (ADF) of the proximal trachea,
showing no airway compromise; (B) bronchoscopic view from the proximal trachea showing a displaced airway stent incompletely covering
the ADF and protruding into the esophagus; (C) bronchoscopic view after repositioning the airway stent and placing an esophageal stent; (D)
bronchoscopic view after placing a second overlapping airway stent to completely cover the ADF.

to different airway size and usually provide a good seal of the
ADF. They can be fully covered or partially covered. Partially
covered stents tend to embed in the mucosal wall making
them less prone to migration, but have a higher rate of tumor
ingrowth and granulation tissue (17,22). Fully covered stents
have a higher rate of migration (17).
Silicone stents have similar radial force but require rigid
bronchoscopy for insertion and tend to have a higher rate
of migration. They are designed with outer studs to prevent
migration and cannot conform to the airway anatomy,
which may decrease their sealing effect.
Complications of airway stenting
The most serious complications of airway stenting are

© Journal of Thoracic Disease. All rights reserved.

bleeding, enlarging or recurrent fistula, stent migration
with recurrent aspiration, airway compromise and death.
These events usually occur as a result of pressure necrosis
and tissue erosion.
During long-term follow-up, recurrent fistula occurred
in 13% to 66% of patients (20-22). Massive bleeding can
occur immediately after stent placement (20,22), or at a
later stage as reported by Wlodarczyk (7/31 patients) (22),
and Wang (2/63 patients) (8).
In a review by Herth et al., respiratory failure requiring
less than one day of mechanical ventilation occurred in 7 out
of 112 patients (6%) after airway and esophageal stenting (21).
Minor complications such as chest pain, dysphagia, foreign
body sensation, coughing and stent migration are frequent
and can occur in up to 40% after stent placement (1).
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Suspected ADF
Contrast esophagogram confirming ADF
Bronchoscopy with airway assessment

Airway narrowing

Carinal involvement

Airway stent

Y stent

Esophageal stent

No airway narrowing

Simultaneous EGD with
esophageal balloon inflation

Airway narrowing
Airway stent
Esophageal stent

No airway narrowing
Esophageal stent
Contrast esophagogram

Persistent leak

No leak

Airway stent

Oral diet

Contrast
esophagogram
Persistent Leak

No leak

Alternative methods, overlapping
stents, PEG, hospice care

Oral diet

Figure 5 Algorithm for management of aerodigestive fistula
(ADF) (16,21,22,26). EGD, esophagogastroduodenoscopy; PEG,
percutaneous endoscopic gastrostomy.

B

A

C

with TE fistulas. Despite the small number of patients
evaluated, these techniques carry the potential of closing
the fistula without the need for major interventions.
However, one has to remember that technical success with
all these methods does not always translate into clinical
success (1).
Over-the-scope-clips (OTSC)
OTSC were introduced as a mean to close deep wall
lesions (Figure 6). First reported in 2007 (28), the device
uses a shape-memory allow (Nitinol). Much larger that
the older through-the-scope (TTS) clips (29), they are
deployed using an applicator integrated into the tip of
an endoscope. The devices are available in several sizes
(11, 12, and 14 mm), depth (3 and 6 mm) and type of teeth (30).
Tissue suction is needed for successful application; hence,
the fistula tissue needs to be soft and extensible (31). As a
result, the clip is typically applied to the gastrointestinal
side of the ADF. Overall, they appear to be more effective
in treating perforations and leaks compared to fistulas (32),
possibility related to the inability to completely approximate
the borders that are frequently fibrotic. The technique
can be used in combination with other modalities (1), such
as esophageal/airway stenting and endoscopic sutures,
potentially increasing its chances of clinical success.
Another OTSC system called Padlock Clip (Aponos
Medical, Kingston, NH, USA) was more recently
introduced. It has the advantage of being located alongside
the shaft of the endoscope, and therefore not requiring the
working channel for deployment. Armellini et al. described
its use in a small case series that included two patients with
ADF (30). Technical success was obtained in all patients.
Larger studies to determine its role in the management of
such patients are needed.
Cardiac septal defect occluder

Figure 6 Different types of over-the-scope clips (27). (A)
Atraumatic version used for gastrointestinal bleeds; (B) traumatic
version used for closure of leaks; (C) gastric fistula closure version.

Other techniques
Several other therapies have been reported in patients

© Journal of Thoracic Disease. All rights reserved.

Another potential method of managing TE fistulas is the
use of atrial septal defect (ASD) and ventricular septal defect
(VSD) occluders. Made of nitinol, the dumbbell-shaped
device is made of two discs of different diameters, connected
by a thin waist. Deployed with the aid of fluoroscopy, each
disc is positioned on one side of the fistula. Inflammatory
response with granulation tissue and re-epithelialization
over the device may occur. The clinical experience
using these occluders in TE fistulas is limited (33).
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Device migration into the airway has been reported (34,35).
Septal button
ADF fistula closure has been attempted using silicone septal
button that are designed to close nasal septal perforation.
Schmitz et al. described the use of a septal button to
successfully close a TE fistula after total laryngectomy in
a case report (36). This resulted in improving the patient’s
quality of life after failing standard therapies.
Fibrin glue
Closing TE fistula using fibrin glue has been described,
mainly in the pediatric population. Made of thrombin and
fibrinogen, fibrin glue has the advantage of immediate
coagulation when calcium and factor XIII are added
(through the conversion of fibrinogen to fibrin). If
successful, it leads to rapid closure and scarring of the
fistula. It can only be used in small fistulas, and one has to
be careful about the possibility of major scope damage if the
glue flows into the working channel (31). In a retrospective
analysis that included 26 patients with esophageal fistulae
or leakages, the application of fibrin glue was successful
in nine cases (37). The remaining patients required other
endoscopic/surgical interventions or continued to have
persistent fistula/leakage. In the same study, 9.6% of
the patients developed an abscess after the endoscopic
intervention.
Polyglycolic acid (PGA) sheets
Another novel technique is the use of PGA sheets to
promote the closure of TE fistulas. These are bioabsorbable
polymers used during surgery to prevent delayed
perforation by increasing the strength of sutures (29).
Combined with fibrin glue, reports have described their
use to enhance the closure of esophago-pulmonary fistula
and esophago-bronchial fistula (38,39). More studies are
needed to confirm their efficacy and apparent safety in this
population.
Mesenchymal stem cells
Transplantation of mesenchymal stem cells is another
interesting technique that could allow the closure of a
fistula. Cells harvested from the bone marrow are injected
into the defect, allowing it to close. In a recent case report,
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Petrella et al. used this technique to close a broncho-pleural
fistula after a pneumonectomy (40). Even though we could
not find any report on using this technique in the treatment
of TE fistula, this could potentially be done for small
defects.
Others
In a case of distal esophago-pleural fistula secondary to
Boerhaave’s syndrome, Adler et al. used a combination of
heat probe and endoscopic suturing to achieve a complete
closure of the fistula (41). This technique could potentially
be useful in the management of ADF. Other techniques
include the use of biodegradable stent. However, the
experience is limited to the pediatric literature (31).
Prognosis
Studies looking into prognostic features in patients with
ADF suggest that achieving complete sealing of the ADF
after stent therapy is associated with longer survival (80 vs.
242 days, P<0.01) (20).
It appears that the location of the ADF may affect
survival as well. A lower survival was noticed in patients
with right mainstem involvement when compared to ADF
involving the trachea, left main bronchus and the carina (21).
From the esophageal side, proximal esophageal location
had the shortest survival (4.2 months) compared to distal
location (7.8 months). Mid esophageal locations have an
intermediate survival of 6 months (1).
Performance status (ECOG 3 or 4), pulmonary infection
at the time of SEMS placement, and prior radiation therapy
were also independent predictive factors associated with
lower overall survival after stent placement (18).
Conclusions
Malignant ADF is a devastating condition with high
morbidity and mortality. Airway and esophageal stenting
remain the standard of care and is shown to significantly
improve the quality of life and survival of these patients.
Although more studies are available to guide our choice of
therapy, high quality trials to establish the efficacy of each
intervention are needed.
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